Opinion on Biotech in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sanofi-Aventis/Regeneron: negative trial data may signal the end for aflibercept in lung cancer

New data indicate that the addition of aflibercept to docetaxel as a second-line treatment for patients with non-small cell lung cancer failed to improve overall survival in a Phase III trial. On the basis of these results and given the competitive landscape of the non-small cell lung cancer market, it is unlikely that Sanofi-Aventis and Regeneron will pursue an approval for this indication.

Published By Datamonitor
15 Mar 2011
CommentWire
CommentWire

Roche: Q3 results highlight dependence on big three MAbs

Roche's Q3 2010 and year-to-date sales are down on the year prior, due primarily to a large decline in demand for the antiviral Tamiflu, although the company's impressive MAb trio of Avastin, Herceptin and MabThera continue to provide strong sales. However, Roche is looking to lower its dependency on these blockbusters, having inked a deal with InterMune for hepatitis C small molecule danoprevir.

Published By Datamonitor
14 Oct 2010
Expert View
Expert View

Roche/Genentech: Avastin to lose metastatic breast cancer indication and associated sales in the US

The FDA has recommended that metastatic breast cancer be removed from Avastin's label after reviewing survival data from Phase III clinical trials. Roche/Genentech has requested a public hearing about the decision, as the removal of breast cancer from the label will impact the drug's US sales. Furthermore, the decision indicates a new level of expectation for Avastin in terms of clinical outcomes.

Published By Datamonitor
17 Dec 2010
Expert View
Expert View

Roche/Genentech/Biogen Idec: US approval will boost Rituxan dominance

The FDA has approved Rituxan for first-line maintenance treatment of patients with advanced follicular lymphoma that responded to initial treatment with Rituxan plus chemotherapy. Sales are expected to increase across the seven major markets following the FDA's decision and, as a result, Rituxan looks set to dominate in this indication.

Published By Datamonitor
02 Feb 2011
CommentWire
CommentWire

Prolia: useful, but not quite revolutionary

Having received approval in both the US and Europe within the space of a few days, Datamonitor expects Amgen's osteoporosis antibody Prolia to achieve sales of over $850m across the seven major markets by 2019. However, despite its first-in-class status, Prolia is unlikely to revolutionize the current treatment algorithm, as existing unmet needs remain.

Published By Datamonitor
03 Jun 2010
CommentWire
CommentWire

Merck Serono: cladribine's failure is a big setback for the company, not MS patients

Swiss drugmaker Merck Serono has announced the discontinuation of additional trials for cladribine and the withdrawal of the product from the Russian and Australian markets, showing that the firm has decided to cut its losses and accept a costly failure. The decision to discontinue a once potentially blockbusting therapy is a huge setback for Merck and its multiple sclerosis portfolio.

Published By Datamonitor
22 Jun 2011
CommentWire
CommentWire

Jazz Pharmaceuticals/UCB: fibromyalgia beckons for narcolepsy drug

New positive top-line results from a second Phase III clinical trial of sodium oxybate in fibromyalgia show that the drug is on track for FDA approval. As such, the treatment is set to enter the market as the fourth drug to be approved for fibromyalgia in the US. Despite impressive efficacy data, however, prescriptions are likely to be limited by accessibility, price and convenience.

Published By Datamonitor
26 Jun 2009
CommentWire
CommentWire

J&J: looking to expand in the vaccines space

After purchasing an initial 17.9% stake in 2009, Johnson & Johnson has announced that it is in advanced discussions to acquire the remainder of Dutch biotech firm Crucell for the equivalent of $2.3 billion. The move is in keeping with the current trend of Big Pharma companies expanding into vaccines, and will provide J&J with a strong business upon which to build its interests in this area.

Published By Datamonitor
20 Sep 2010
CommentWire
CommentWire

ICAD 2009: tau emerges as a viable target for immunotherapy in Alzheimer's

Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.

Published By Datamonitor
22 Jul 2009
Expert View
Expert View

ICAD 2009: beta-amyloid remains center stage at Alzheimer's disease conference

In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.

Published By Datamonitor
22 Jul 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.